Clinical trials: Influenza Virus Infection
Influenza
Randomized Influenza Vaccine Evaluation of Immune Response
Licensed influenza vaccines are manufactured with a variety of technologies. The majority are split, inactivated vaccines derived from egg-adapted, high growth reassortant viruses.
- Trial name
- RIVER (NCT03598439)
- Testing
- Standard IIV4, Recombinant, Cell-culture
- Where
- United States
- Volunteers
- 366 people
- Sponsor
- Marshfield Clinic Research Foundation
Pregnancy Related, Influenza Virus Vaccine Adverse Reaction
Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy
This is a nationwide cohort study to assess maternal and fetal outcomes following vaccination with a quadrivalent influenza vaccine (QIV) during pregnancy.
- Trial name
- NCT04579822
- Testing
- influenza vaccine
- Volunteers
- 300,000 people, healthy volunteers welcome
- Sponsor
- Sungkyunkwan University
Healthy
Tonsillar Cytokine Expression After Allergen and/or Virus Intervention
Hypotheses 1. Immunotherapy induces tolerogenic effects to allergens in T cell regulation in tonsils. 2. Influenza vaccination induces a strong interferon response and decreases Th2 response in tonsils. 3.
- Trial name
- Tons2 (NCT01924208)
- Testing
- Timothy, Phleum pretense, Live attenuated influenza virus, Timothy + attenuated influenza virus
- Where
- 4 sites in Finland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Influenza
Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants
Severe influenza respiratory disease is increasingly recognized in children. Influenza hospitalization rates in high-risk infants, such as premature infants, are increased some five-fold over rates in other children.
- Trial name
- NCT01194297
- Testing
- Live attenuated influenza vaccine, Inactivated influenza vaccine
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.
This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated quadrivalent influenza vaccine, in comparison with a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1), and…
- Trial name
- NCT02214225
- Testing
- Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
- Where
- 33 sites in United States
- Volunteers
- 3,484 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults
- Trial name
- NCT00958126
- Testing
- CSL425
- Where
- 11 sites in United States
- Volunteers
- 1,313 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza A Virus
A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation
The purpose of this study is to compare the rate and extent of absorption of JNJ-63623872 following administration of a single dose as three different concept formulations with that following administration of the current…
- Trial name
- NCT02659735
- Testing
- JNJ-63623872 300 milligram (mg), JNJ-63623872 600 mg
- Where
- Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
The aim of this clinical study is to demonstrate safety and immunogenicity of Fluzone vaccine. Objective: To describe the safety of the 2012-2013 formulation of Fluzone vaccine, administered in a 1- or 2-dose schedule, in…
- Trial name
- NCT01691326
- Testing
- Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose, Fluzone®; Influenza Virus Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, Influenza
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
- Trial name
- NCT06694389
- Testing
- mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 2,457 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Avian Influenza, Bird Flu
Safety Study of an Oral Vaccine to Prevent Avian Influenza
The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.
- Trial name
- H5N1 (NCT01335347)
- Testing
- ND1.1
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
The goal of this study is to establish that Flublok Quadrivalent is non-inferior to fully licensed (traditional approval status) quadrivalent inactivated influenza vaccine (IIV4) in protecting against laboratory-confirmed…
- Trial name
- NCT02285998
- Testing
- Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine
- Where
- 38 sites in United States
- Volunteers
- 9,003 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Seasonal Influenza
Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)
This study is a phase I, randomized, double-blind, placebo and active comparator-controlled clinical trial to evaluate the safety and immunogenicity of a trivalent split influenza virus vaccine (MDCK cell) developed by Sinovac…
- Trial name
- NCT07889193
- Testing
- Cell-based Trivalent Split Influenza Virus Vaccine (cTIV), Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)
- Where
- China
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to characterize the immunogenicity and safety of 3 doses of GSK's avian flu vaccine GSK 1557484A given at different time intervals to adults aged 18 years or greater who are at increased occupational…
- Trial name
- NCT01045564
- Testing
- GSK influenza virus H5N1 vaccine 1557484A
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)
The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how…
- Trial name
- NCT03023709
- Testing
- Fluzone®, FluMist®
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza, Influenza Prophylaxis
Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting
This study aims to randomly assign close contacts of hospitalized influenza virus patients to receive baloxavir marboxil prophylaxis, oseltamivir prophylaxis or no antiviral prophylaxis and monitor the incidence of clinical…
- Conditions
- Influenza, Influenza Prophylaxis, Nosocomial Infection
- Trial name
- NCT06762587
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- China
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Influenza
Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of the candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above
- Trial name
- NCT00363077
- Testing
- GSK1247446A Group, Fluarix™
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers
The purpose of this study is to evaluate the safety and immunogenicity of a sublingual administration of NSV0001 in healthy male volunteers.
- Trial name
- NCT02955030
- Testing
- NSV0001, Influenza HA vaccine "Biken HA"
- Where
- Japan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Nitto Denko Corporation
Influenza, Respiratory Tract Infections
Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2
This trial is taking place in Los Angeles, CA among patients from primary care practices within the UCLA Health System. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above…
- Trial name
- NCT04110314
- Testing
- Portal Reminders for Influenza Vaccination: Gain-framed, Portal Reminders for Influenza Vaccination: Loss-framed, Pre-commitment prompt
- Where
- United States
- Volunteers
- 430,636 people
- Sponsor
- University of California, Los Angeles
Influenza
Influenza Burden Assessment in the United Kingdom, 1996-2008
The study will assess the burden of influenza by age, risk status, vaccination status and influenza subtype, in order to create a complete profile of the burden of influenza-related morbidity and mortality in United Kingdom from…
- Trial name
- NCT01520935
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP
This randomized, open-label trial will assess humoral and cell-mediated immune responses to cell culture-based and recombinant unadjuvanted quadrivalent influenza vaccines compared to conventional egg-based unadjuvanted…
- Trial name
- NCT03722589
- Testing
- Flublok, Flucelvax, Fluarix
- Where
- 2 sites in United States
- Volunteers
- 944 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.